9 "Patrick Loehrer, Md" clinical studies found.

• IUCRO-0031; Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma

  The primary objective of this study is to obtain blood and tissue samples for laboratory evaluation.

  Patrick Loehrer, Md

• Genotype-directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab

  This study involves standard combination chemotherapy treatment for colon cancer, 5-Fluorouracil (5FU), leucovorin and irinotecan (known as FOLFIRI), plus bevacizumab ...

  Patrick Loehrer, Md

• A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

  This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination ...

  Patrick Loehrer, Md

• Phase II Randomized Double-Blind Study of mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients HCRN GI14-198

  The purpose of this study is to find out what effects, good and/or bad, there are to adding the ...

• Phase II Trial of Panitumumab Nivolumab and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma

  The purpose of this research study is to learn more about the safety and anti-cancer activity of a 3-drug combination ...

  Patrick Loehrer, Md

• A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

  This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high ...

  Patrick Loehrer, Md

• Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer ...

  This phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone ...

  Patrick Loehrer, Md

• Tissue Procurement Protocol for the Developmental Therapeutics Clinic National Cancer Institute (NCI)

  The purpose of this study is to obtain samples for research purposes from tests performed for clinical indications or research ...

  Patrick Loehrer, Md

• A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and ...

  In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has ...

  Patrick Loehrer, Md